GlassScriptPhysician profile
Gustavo Serrano
NPI 1396732442
$5,668.39
in general payments reported to CMS, 2019-2025
39 companies · $1,133 in 2025
The $1,133 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,025 · 2020: $977 · 2021: $945 · 2022: $586 · 2023: $482 · 2024: $521 · 2025: $1,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,117 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,116.56 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $653.84 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $653.44 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $372.92 | 2019-2025 | Jynarque |
| Glaxosmithkline, LLC. | $294.14 | 2019-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $290.61 | 2021-2025 | |
| Horizon Therapeutics Plc | $286.47 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.52 | 2020-2025 | Jardiance |
| Amarin Pharma, INC. | $236.96 | 2020-2022 | |
| Abbvie INC. | $234.05 | 2019-2025 | Vraylar |
| Amgen INC. | $230.63 | 2020-2025 | Otezla, Repatha, Otezla |
| Allergan, INC. | $224.48 | 2019-2020 | |
| Calliditas Therapeutics US INC. | $201.97 | 2022-2025 | Tarpeyo |
| Sanofi-Aventis U.S. LLC | $193.26 | 2019-2023 | |
| Novo Nordisk INC | $180.53 | 2019-2023 | Rybelsus, Ozempic |
| Renalytix Ai, INC. | $148.11 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gustavo Serrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.